Navigation Links
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
Date:6/30/2009

- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program -

- Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer Utility -

TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed the planned patient enrollment in its U.S. Phase I clinical trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. In a presentation of preliminary data from this trial at the 2009 ASCO Annual Meeting last month, the study's principal investigator at MD Anderson Cancer Center reported that bavituximab was generally safe and well-tolerated, with a predictable pharmacokinetic profile. In these patients, a maximum tolerated dose had not been reached even at the highest planned dose level. Peregrine has now begun designing additional bavituximab cancer trials based on findings from this Phase I study and the company's ongoing Phase II combination therapy trials in breast and lung cancer.

"Completion of patient enrollment in this Phase I trial is a significant milestone for the bavituximab cancer program," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "We believe data from this study, along with our ongoing Phase II lung and breast cancer trials, set the stage for advancing the bavituximab oncology program into later-stage clinical studies. The safety data collected from the diverse cancer types in this study are encouraging as we plan for expansion of the bavituximab cancer program in the coming year. We look forward to sharing more data from the ongoing cancer trials as patient treatment and follow-up continue in this study and in our three ongoing Phase II bavituximab cancer tri
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... The ... Pain and Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity ... often, although it is not to say that one causes the other. Rather, there ...
(Date:8/4/2015)... ... August 04, 2015 , ... assistPoint Partners, LLC is ... oncology patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, ... enterprise level, cloud-based application and workflow solution. This provides cancer center patient advocates, ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED ... on hard hats that have a flip-up face shield. The sleek contours of the ... without having to remove their headlamp when raising or lowering their face shield or ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide ... Power Products is expanding its reach in Texas. Effective July 1st of this ... North Texas generator division. With the North Texas acquisition, Worldwide Power Products ...
Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2
... News) -- Simple precautions will help keep you safe and ... for winter or put up holiday decorations, experts say. ... treated in U.S. emergency departments for holiday decorating-related falls, according ... of those injuries were caused by falls from ladders. ...
... find out whether a new drug or treatment makes ... life, according to a commentary published online December 3rd ... . Instead, most trials now are designed to detect ... which may not be clinically meaningful, write Alberto Ocana, ...
... -- New research explains why immune function actually improves in a ... cases, the virus has mutations that protect it against some HIV ... the researchers at the Mayo Clinic in Rochester, Minn. This ... equally bad for the immune system, the authors noted. "These ...
... leads to a decrease in adult stem cells and ... the offspring, according to new research from the University ... annual Society for Neuroscience meeting in San Diego in ... for behavioral problems such as attention-deficit hyperactivity disorder (ADHD) ...
... FRIDAY, Dec. 3 (HealthDay News) -- The impending extinction ... remove an important buffer against the transmission of infectious ... by the U.S. National Science Foundation and National Institutes ... the U.S. Environmental Protection Agency, focused on how the ...
... quarter of Americans live in rural areas, which consistently ... areas. Among the complex causes for this disparity is that ... almost 4 out of 10 rural residents live at ... the time, transportation, and financial resources for travel to urban ...
Cached Medicine News:Health News:Assessing positive outcomes of phase III trials 2Health News:Nicotine exposure in pregnant rats puts offspring at risk for learning disabilities 2Health News:Species Extinctions May Spell Trouble for Human Health 2Health News:ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA 2
(Date:8/4/2015)... JOLLA, Calif., Aug. 4, 2015   Regulus ... biopharmaceutical company leading the discovery and development of ... and highlights for the quarter ended June 30, ... highlights.  "The second quarter of ... of progression for Regulus," said Paul Grint, M.D., ...
(Date:8/4/2015)... , Aug. 4, 2015 Levi & Korsinsky ... ("Biogen" or the "Company") (NASDAQGS: BIIB) for possible violations ... and certain of its officers and/or directors have violated ... of 1934.  On Friday, July 24, 2015, prior to ... quarter 2015 financial results. Among other things, the Company ...
(Date:8/4/2015)... Aug. 4, 2015  Sutro Biopharma today announced ... Ph.D., as vice president of alliance and project ... in the management of Sutro,s collaborative partnerships and ... antibody-drug conjugates, bispecific antibodies and antibody-based therapeutics targeting ... than 22 years of experience in the biopharmaceutical ...
Breaking Medicine Technology:Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws -- BIIB 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2
... 2012 Ziehm Imaging, leading developer, ... award-winning product portfolio at this year,s Charing Cross ... ), its UK distribution partner, Ziehm Imaging showcases ... cardiologists to provide them with a flexible, cost-efficient ...
...  NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the first quarter ... before the opening of the financial markets. ... also host a conference call at 9:00 a.m. Eastern ...
Cached Medicine Technology:CX 2012: Elevating the Boundaries of Interventional Imaging with Mobile C-arms 2NxStage® to Report First Quarter Fiscal 2012 Financial Results 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: